Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided an update on the U.S. launch of VYKATTM ...

Discover key insights from Soleno Therapeutics' Q2 2025 earnings call, highlighting Vykat XR's strong launch, revenue growth, EU expansion efforts & ...

TD Cowen raised the firm’s price target on Soleno Therapeutics (SLNO) to $120 from $115 and keeps a Buy rating on the shares. The firm notes Soleno reported impressive Vykat XR revenue of $33M in its ...

Analysts are estimating that Soleno Therapeutics will report an earnings per share (EPS) of $-0.53. The market awaits Soleno ...

Soleno Therapeutics, Inc. (SLNO) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.53. This compares to a loss of $0.57 per share a year ago. These ...

Soleno Therapeutics Inc. (NASDAQ:SLNO) is one of the best performing mid cap stocks so far in 2025. On July 10, Soleno Therapeutics announced that the sales of its new Prader-Willi disease drug, ...

--Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced updates to its Board of Directors.

Soleno Therapeutics's Current Market Status With a volume of 2,551,056, the price of SLNO is up 8.21% at $51.54. RSI indicators hint that the underlying stock may be approaching overbought.

Soleno Therapeutics, Inc.'s NDA submission of DCCR for the treatment of patients with PWS accepted by the FDA with Priority Review with a PDUFA date of December 27th of 2024.

Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases ...